Infernal Ramblings
A Malaysian Perspective on Politics, Society and Economics

On Economic Freedom

Written by johnleemk on 9:04:03 am Dec 17, 2006.
Categories:

Liberty is often regarded as an ideal - as something to be strove for simply because it is good. Liberty is usually thought to be an end in itself, especially by Western liberals. Libertarianism, which espouses the maximisation of personal and economic freedom, is founded on the thinking of economists like Friedrich Hayek and Milton Friedman - both of whom often spoke of freedom as an end in itself. Hayek's seminal work, The Road to Serfdom, highlights his view that impediments to economic liberty inevitably result in, well, serfdom.

Now, I personally have viewed myself as libertarian for about the past half decade. I believe you have the right to do whatever you please, as long as you don't harm anyone. If you want to watch pornography, go ahead. If you want to stick your penis in another guy's anus, go right ahead. Just don't do it while I'm watching. Similarly, I believe that society should rely on the free market to answer the basic economic questions of what to produce, who to produce it for, how much to produce, how to produce it, etc.

I have always wondered, however, about how to reconcile the free market with the problem of poverty. I do not speak just of the unemployed who just scrape by in life, but of those who die of the easily solved problem of hunger. How can a system that leads to the overproduction of agricultural goods also lead to deaths from starvation? If society can afford to produce life-saving medicines at inexpensive prices, why should there be millions of suffering people unable to get the medication they need? Why should economic freedom be an end in itself?

Like many, I have come to the conclusion that economic freedom is not and should not be an end in itself. (This may seem painfully obvious to a large number of people, but you'd be surprised how many libertarians think of freedom as the ultimate goal society should strive for.) The reason simply is that an economic system exists only to resolve the basic economic problems of production. The ideal economic system is not that which provides the most freedom, but that which can produce the most amount of goods for the lowest cost to society.

Now, most people, after witnessing the insanity of the present state of things, turn into proponents of a highly regulated market, with price controls, nationalisation of key industries, and the like. But a study of orthodox economic theory reveals that the free market is not and should not be the anarchistic market. A free market must operate within a legal framework designed to fight the problems of market failure. (Notice that this is what orthodox economic theory, as espoused by the vast majority of academic economists, suggests. Unconventional economists such as Hayek have argued that a less regulated market than conventional economics would advocate is more efficient.)

I have written in the past of how the ideal market would operate - with strict restrictions on monopoly power, and the incorporation of subsidies and indirect taxes to address externalities. It may be noticed, however, that I have not produced a solution to the problems of hunger and inadequate supplies of lifesaving medication that I mentioned above.

The reason for this is that these problems have not been created by the free market. The main reason we have an excess glut of agricultural goods in developed countries is because developed countries can afford to subsidise the hell out of agricultural production. The European Union, for instance, is known for its mountains of grain and lakes of wine which nobody will buy, because the governments of Europe have encouraged their producers to overproduce by means of subsidising production. And why won't these farmers sell to starving African nations? Because of protectionism - the World Trade Organisation enforces "anti-dumping" regulations, which ban the export of goods at prices deemed excessively low by the WTO. For the same reason, developing countries cannot export their goods to the developed nations. This situation would never occur in a truly free market, because a truly free market does not have ridiculous protectionist measures like anti-dumping regulations.

Similarly, government intervention has created the problem of inflated drug prices, which keep lifesaving pills out of the hands of those who need them most. The reason for this is the government-created monopolies drugmakers have on their inventions. Each drug manufacturer gets a monopoly on its products until a certain date, after which their recipe becomes public. Without the patents, there would be no monopoly, allowing anyone to produce and sell the drug at will - and the ensuing competition would work to drive prices down.

The question of why we do not simply phase out patents is not as simple to answer as why we keep cheap goods out of our countries' borders. The latter is easily answered: local firms and their employees would much rather keep the competition away. The former, however, is not, because without patents, there would be very little incentive for drugmakers to research and develop new drugs. Developing a drug is very costly and time-consuming - it can take as long as a decade to bring a new drug to market. Without patents, there would be nearly no incentive to innovate - not when once you bring the drug to market, competitors copy your product and drive your profit margins down to practically nothing.

If this sounds familiar, it's because the free rider problem has arisen. The pharmaceutical companies' rivals are the free riders, getting the benefits of the new drug for free. There is a positive externality at work here, and so the way to approach it would naturally be to correct it. Governments, however, have chosen to correct this problem by enforcing drug patents - granting pharmaceutical companies a monopoly on their products for a certain length of time. This is not a very desirable solution, however. Replacing one market distortion with another cannot be very helpful.

Alas, this is a problem that remains unsolved. Nobody has cracked this nut yet, and so drug companies continue to reap tremendous profits from their monopolies, while those who cannot afford their expensive medication continue to suffer. Some possible solutions have been proposed, such as a bounty for innovation - the government would pay a lump sum to the inventor of a new drug, with the price set by an auction. (I am not too clear on the specifics.) But still, this proposal has yet to be taken up by any government in the world. If (and hopefully when) a feasible solution is implemented, you can mark my words that its creator will win the Nobel Prize for Economics.

These misattributed problems of the market aside, there also remain some crucial issues that are undeniably caused by the market. I will tackle perhaps the biggest and most controversial one here: the problem of globalisation. In nearly every developed or semi-developed country around the world, there exists a protectionist movement seeking to erect barriers to integration with the global economy. This is especially marked in the United States, with the recent election of several protectionists to Congress such as Senator-elect Sherrod Brown of Ohio and Senator-elect Jim Webb of Virginia, to say nothing of the numerous Representatives-elect in the House.

There are many reasons for protectionism, some less reasonable than others. Often, it is argued that "infant industries" need to be protected so they can build themselves up without worrying about being buffeted by global market forces. This may or may not hold water, but from our experience here in Malaysia, it is extremely difficult to wean these infant industries off the teat of government protection once they get up and running. For example, the national car manufacturer, Proton, remains heavily protected by government import tariffs and the subsidisation of Proton's production lines despite having been in business for two decades.

Another argument in favour of protection is that countries should not render themselves overreliant on imports, in case a key trade partner suddenly pulls the plug. The problem with this line of thought is that you cannot have your cake and eat it. If you want to be truly self-sufficient, you have to produce everything at home. Even if all that is sought is self-sufficiency in a few key goods, it is extremely difficult to attain production levels that will meet domestic demand. Furthermore, it will be nearly impossible to export these goods because they have to be sold at prices above those of other countries who have a natural comparative advantage in their production, and whose goods would have been imported had there been no self-sufficiency policy in place. At the same time, other goods which the country has a comparative advantage in will be underproducing, because they have been neglected at the expense of those self-sufficient policy-targeted industries. The problem can be reduced if we do not seek total self-sufficiency, but in such a case, what is the point? Either you are completely independent of other countries, or you are not. A few extra hundred thousand tonnes of rice won't make much difference if you still need imports to feed your people.

Retaliation is also cited in opposition to globalisation. Many countries, it is noted, impose protectionist tariffs and quotas on our exports, while subsidising their own exports. It is thus only fair and just for us to impose our own protectionist measures to erase this unfair advantage. This argument was popular in the 1980s and early 1990s during Japan's economic ascendancy. The problem with this tit-for-tat approach is that it inevitably results in a worser outcome for everyone. To take the colourful analogy applied by one Cambridge economist, should we block up our harbour because another nation has rocks in their's? Two wrongs don't make a right.

The most-cited argument, however, is that free trade harms workers by destroying local jobs. Protectionists argue that trade pacts result in the loss of jobs to trade partners. The problem here is that this only examines one side of the equation - the job loss is more than offset by the gains made in cheaper imports and the freeing up of resources to allow each country to focus on what it can do best. Protectionism would benefit those workers whose jobs are spared, but harm the whole country by forcing it to continue overpaying for imports and preventing the creation of jobs in industries where the country's comparative advantage lies. This is why legislative bodies, where individual members are accountable to their respective constituencies, tend to be protectionist in nature, while leaders elected by the whole country tend to support free trade.

A corollary to the above argument is the "race to the bottom". Protectionists suggest that all globalisation will result in is a race to the bottom - a race where capital flows to the country with the lowest costs of production, where environmental and labour regulations are most lax, where wages are lowest, leading to a world with very cheap goods and services, but where capitalists exploit and abuse people and nature to the fullest. This argument, if thought through to its logical conclusion, holds no water. For one, there is a finite number of countries in the world. If as wages rise, firms shift their operations to another country with lower costs, eventually there will be nowhere to run. The result will then be that at some indeterminate point in the future, wages everywhere will start to rise. And looking at the up-and-coming developing countries, it's quite clear that the race to the bottom is a myth. Direct investment is not as mobile as one might think; it is impossible to uproot whole manufacturing plants from one country to another. Firms tend to stay put, and living standards everywhere tend to rise. Vietnam, China, India - their economies are growing by leaps and bounds, and living standards (as measured in GDP per capita) are rising in tandem. It is not surprising that this has come about only now, after they have taken down their barriers to trade (Vietnam and China are still communist in name, but not in fact; India was run by socialist governments until the 1980s when the present Prime Minister, economist Manmohan Singh, became Finance Minister and reformed the economy). Eventually, they will rise to a similar level as South Korea and Japan have - there is no such thing as a race to the bottom.

That is not to say that the problems globalisation creates aren't real. Developed economies' firms do take advantage of cheap labour and lax regulations, and meanwhile workers in developed countries whose jobs are eliminated suffer. The former, however, is a problem that will dissipate as economies develop. Implementing policies such as the minimum wage (which, by the way, is controversial among economists for interfering with the labour market) in developing economies would hurt more than they help, possibly stalling development. The time is not yet ripe. As for the problem of workers in developed countries, the problem is that the industry they have specialised in no longer has the comparaitve advantage in the global economy. The solution is retraining. Note that most who have lost their jobs in developed countries due to globalisation are the middle-aged. New entrants to the job market will have had the chance to specialise in an industry where their country has the upper hand, and so will have greater job security.

Many problems people have with economic liberty arise from misunderstanding how markets are supposed to function, and from a failure to examine the fundamentals that have created the issues we struggle with. Often, even the proponents of capitalism fail to grasp that markets are only a means to an end. An economic system is supposed to allocate resources efficiently, not lead to unrestrained freedom. Even Milton Friedman, whose libertarian thinking has been rejected by many economists, was in favour of a negative income tax - redistributing income to the poorest through direct transfer payments. We would all do well to become students of economic thought, because it teaches us invaluable lessons about the world, and how we can never jump to conclusions such as "Globalisation is bad" or "More economic freedom is invariably good" from simple observations such as "Globalisation destroys jobs" or "More personal freedom is invariably good".


If you'd like to keep informed about updates to the site, consider subscribing to our web feed:

Infernal Ramblings is a Malaysian website focusing on current events and sociopolitical issues. Its articles run the gamut from economics to society to education.

Infernal Ramblings is run by John Lee. For more, see the About section. If you have any questions or comments, do drop him a line.


Comments

Thoughts? Comments? Discuss this and other ramblings at the forums.
(Alternatively, contact the author privately.)

Related comments from forum thread "Medicinal Monopolies":
johnleemk
Infernally Rambling Thoughtless Mind
Head Administrator
Posts: 948
IP Logged

Posted at 6:37:34 am Nov 2, 2005
One of the major problems I see facing modern medicine is the appropriate pricing of medicines. You see, it costs a lot to develop modern drugs - you not only have to pay for researching and marketing it, but also for test trials, etc. Furthermore, it also involves a lot of investment in time on the part of medical companies - a lot of time, on the scale of decades, even. If a drug doesn't pan out by say, not getting approval from the US Food and Drugs Administration, they may have wasted millions of dollars on nothing. As a result, medicinal companies need to charge higher and higher prices to recoup their costs.

However, to be able to charge such high prices, the demand for the drug must not be very elastic (the customers must not be turned off by a huge rise in the price of the drug). And in a market where other drug companies can be selling similar medicines, demand tends to be rather, well, elastic. This makes it financially unfeasible to develop drugs, especially complicated ones like those for AIDS or cancer. After all, what's the point when your competitor will be selling the same drug as yours under a different name within a few months? You might call this market failure, but the market has done nothing wrong; it's just impossible to profit from developing complex drugs.

Therefore, the governments of the world have stepped in to encourage drug development by awarding 20-year patents to drug discoverers. For 20 years, the company that discovered the drug will be the only one in control of who gets the drug - it's a monopoly. Now, this might be a good thing, except for the fact that once again, you've got the nasty market to contend with - the prices are high, remember? With diseases that affect mainly the poor, such as AIDS, this can cost millions of lives for the sake of a few dollars.

Sure, you could argue that the government could step in, but how? If it forces companies to lower their prices, there will no longer exist any incentive to develop new drugs. If the government itself subsidises drugs, there will be an incredible cost to taxpayers that many would find unconscionable. (Hey, remember the prices were artificially jacked up by the gifting of a monopoly to the drug manufacturers?) Arguably, socialism has come full circle - the interference in the market has come back to bite socialists in the ass. (Even though the measure is pro-business, remember it interferes with the workings of a free market.)

Some would argue that the monopoly is a natural monopoly, and that we should step aside and allow the free market to work. Such is the economic orthodoxy, but it's easy to say this to an audience of educated (and probably not dieing or starving) professionals. It's another thing to say this to the face of those who will face a struggle with cancer or AIDS for every day of the rest of their lives. A humane but practical solution has to be found.

Of course, there are also the even more extremist who would question that statement. After all, worshipping the omnipotent, omniscient free market is the "in" thing of economics nowadays. However, anyone who has ever bothered to read and comprehend an undergraduate economics textbook knows such a "free market is always right" stance to not only be wrong but downright dangerous. The free market is a means to an end, not an end in itself.

Economics teaches that the market exists only to produce and allocate goods and services. Once you have understood this, all the romance and mysticism of the free market are gone. But if you don't stop there and dig further into your undergraduate textbook, you'll find that the market isn't even always right when it comes to the distribution of goods and services - indeed, it can be horribly, horribly wrong. That's why the term "market failure" has been coined. The market fails when it allows a monopoly or oligopoly to erect barriers to entry, when it allows imperfect information, or when it allows externalisation of costs. The market is an imperfect tool - a good one, mind you, but nevertheless, rough around the edges.

Thus, we return to the original question - how do we provide drugs at an affordable cost without stifling the incentive to research and manufacture such drugs? We've struck subsidies and the outright removal of the patent system without replacing it off our list, so what's next? One common solution is to lower the length of the patents so that the drug recipe will be released into the hands of other companies sooner. This is just tinkering with the system, and offers no real solution. Furthermore, by lowering the length of the patent, the incentive to research costly drugs will also dissipate somewhat.

So we have to cross that one off our list. What's next? Well, here's a thought - an impractical one, but still a thought - drug bounties. Simply, governments would award the first one to come up with a drug that cures AIDS/cancer/whatever a certain amount of money, commensurate with the importance of the drug. This of course has its drawbacks - to be effective, the taxpayers will again have to open their wallets, and the price may be difficult to optimise (how do you know whether you're paying too much or too little for the cure for cancer?).

So, as you can probably tell by now, there is no real answer. There's no solution - at least, one isn't anywhere in sight in the near future. Still, it's quite the challenge, and you mark my words - the man who discovers how to optimise the production and distribution of drugs will win the Nobel Prize in economics. It's quite simple - in this case, there has been no market failure. So now we just have to figure out how to stimulate costly drug production without the help of the market. Well, it's not that simple. But you get my point.
Last five replies (3 comments not shown):
tanstaafl
Member
Posts: 9
IP Logged
Posted at 1:31:12 pm Mar 16, 2007
How exactly does having an FTA reduce or discourage corrupt practices? Anecdotal evidence would seem to suggest that it is neutral or in some cases increases corruption

http://www.counterpunch.com/vargas03122007.html

As John has stated previously in an earlier post, there is really no conclusion that can be drawn at this time on the FTA that is currently being negotiated at this time. However, I am still uncomfortable with how many free trade proponents glibly dismiss the potential downsides without really delivering a solution on how these problems are supposed to be dealt with.

As far as Malaysia is concerned, the last thing it needs right now social turmoil cause by economic disruptions given the "outstanding" calibre of our government and our politicians.
jasoneight
Member
Posts: 3
IP Logged
Posted at 12:24:03 pm Apr 10, 2007
The article in the Sun makes sweeping statements about the MUFTA without providing actual facts and figures. That is probably closer to "intellectual bankruptcy" than the FTA itself.

Malaysia is currently in negotiations with the United States for a Free Trade Agreement (MUFTA) which is expected to ease the way for attracting more foreign direct investment to Malaysia.

Amongst the issues being negotiated is the strengthening of intellectual property rights (IPR) in Malaysia. Even though Malaysia already has high standards of Intellectual Property Rights (IPR) in the form of patents, trademarks and copyright, there is still a need to enhance the IP environment in order to recognize and reward research.

In order to attract foreign investment in the R&D sector, it is important to understand that foreign corporations invest not to make simple products but to produce those with high elements of innovation, creativity and design. This will help to promote foreign direct investment as it makes Malaysia more attractive for foreign investors that have invested heavily in research. This is especially so in the pharmaceutical industry which has been identified as a key growth sector under the Third Industrial Master Plan (IMP3).

US pharmaceutical companies spent US$55.2 billion on R&D in 2006 and there is a great possibility of a fraction of that amount that can be diverted to Malaysia with the FTA. (PhRMA news Feb 12, 2007)

However, there are some unwarranted fears in the industry about the MUFTA provisions on IPR that will cause difficulties to local drug manufacturers who are mainly producing generic drugs. Such fears and apprehensions are largely misconceived because stronger intellectual property (IP) protection does not hurt local generic drug manufacturers or make them lose out. Instead the opportunities for them become better as it will attract investments from large pharmaceutical companies with resulting spin-offs to the local generic drugs manufacturers in terms of joint ventures, contract manufacturing and R&D.

Even China, a nation hardly well-known for its IP laws, has actually passed regulations as early as 2002 to provide for 6 years of data exclusivity as from the date of marketing approval. In the “Regulations for Implementation of the Drug Administration Law,” effective September 2002, the definition of a new drug was modified in accordance with the Trade-Related Aspects of Intellectual Property Rights (TRIPS). The new Patent Law further harmonized China’s patent system with the rest of WTO member countries. In fact, China’s IP protection for pharmaceuticals has gradually been coming into conformity with international standards over the past several years.

The result of China’s IPR strategy is clear with the who’s who of global pharmaceutical companies moving into China in a big way. Today, multinationals have over 600 joint ventures with local companies in China.

AstraZeneca invested US$134 million in a manufacturing plant in Wuxi and is set to invest another US$100 million to open the AstraZeneca Innovation Centre China in 2009. It has a marketing arm that employs 2,500 people and has also created a division to support local clinical trials.

Novartis is collaborating with the Shanghai Institute of Material Medical Research, a leading Chinese R&D institute and it is constructing a US$83 million site for drug production and development in Changshu.

World leading pharmaceutical company Eli Lilly set up a research laboratory in cooperation with its Chinese partner Shanghai ChemExplorer in the Zhangjiang New and Hi-TechTechnological Park in Shanghai’s Pudong New District. World first-class research equipment has been installed in the lab and it has 230 scientists working in China. The China-based R&D team is the US-based firm’s largest R&D group overseas. Eli Lilly has also agreed to transfer its antibiotics manufacturing technology to leading Chinese company Hisun Pharmaceutical Co Ltd. The move is part of Eli Lilly’s US$70 million global initiative to address multi-drug resistant tuberculosis, in partnership with the World Health Organization. It also has a factory in adjacent Suzhou city, east China’s Jiangsu province.

Meanwhile, Pfizer, has invested over US$500 million in China and will also set up a new R&D center in Shanghai with initial spending of US$25 million over the next few years.

In 2002, GlaxoSmithKline (China) Investment Co. Ltd. (GSK) was officially established and became one of the largest multinational pharmaceutical companies in China. GSK has established five legal entities encompassing four manufacturing facilities (three are joint ventures) with a total registered capital of over US$230 million in China. It has offices in 29 major cities (including Hong Kong) with 2,800 employees nationwide. The various companies continue to create jobs and provide training for business managers and professional staff in the pharmaceutical industry, as well as provide business opportunities to local partners and medical professionals.

GSK signed an agreement with China’s Simcere Pharmaceutical Group to manufacture and sell a cheaper version of its bird flu drug Relenza for use in poorer countries. The terms of the licensing deal allows Simcere to manufacture and sell zanamivir, the active ingredient in Relenza, in China, Indonesia, Thailand, Vietnam and other less developed countries.

Relenza, together with Roche’s antiviral Tamiflu, are the only drugs considered effective against the human form of H5N1 influenza, and would be the first line of defense in the event of a worldwide H5N1 influenza pandemic.

Roche has two manufacturing plants in China, one of which is a high tech manufacturing facility in Shanghai producing the cancer medicine Xeloda and the transplantation medicine CellCept. Both Xeloda and CellCept are major medicines in the Roche portfolio. Xeloda is a tumour-activated oral chemotherapeutic agent used to treat breast and colorectal cancer. CellCept, used as a foundation for immuosuppression, helps transplant patients to live a longer and healthier life.

Roche also opened its new R&D center in Shanghai which its fifth Pharma research site globally. The center will work with JiangJiang High Tech Park to promote the district to become a leading biomedical research based epicenter of drug research and discovery in China. In addition, it is working in collaboration with the two Chinese National Human Genome Centers to conduct genetic epidemiology studies to identify genetic predispositions to diseases such as diabetes or Alzheimer’s.

Further more, like GSK, Roche is the maker of Tamiflu, an important bird flu vaccine and the company granted a first sub-license to Shanghai Pharmaceutical Group for the production of Tamiflu for pandemic use in China.

If China can see tremendous benefit of stronger IP protection, certainly Malaysia should be able to recognize the advantages of it as well and not miss the golden opportunity that the MUFTA presents in attracting new FDI and helping us move up the value chain in innovation and R&D.

Fears and apprehensions by our local generic drug makers are largely misconceived as the Government of Malaysia’s outlook on the pharmaceutical industry in general and the generics in particular is very bright. Instead of adopting a negative stance, one should first study the Third Industrial Master Plan 2006-2020 (IMP3) especially at pages 405-420 which clearly identified the pharmaceutical industry as one of the 20 target growth areas. The opportunities are tremendous for local generic drug manufacturers and their growth prospects are very positive.

There were 235 pharmaceutical companies registered with the Drug Control Authority, Ministry of Health in 2005, 148 producing traditional medicines and 87 manufacturing modern medicines. The majority of the companies in the industry comprise small and medium enterprises (SMEs), mostly producing generic drugs.

During the IMP2 period from 1996-2005, domestic investments in the pharmaceutical industry amounted to RM756.5 million or 75% of the total investment while foreign investments were valued at RM250.4 million. For this period, the domestic pharmaceutical market registered an average annual growth of 11 per cent. The sales of locally produced pharmaceutical products grew at an average annual rate of 10.8 per cent, from RM334 million in 1996 to RM852 million in 2005. Exports of pharmaceutical products grew at an average annual rate of 10.6 per cent, from RM194 million to RM494.3 million in 2005. This was a result of a significant expansion of production into a wider range of generic drugs with the expiry of more patented, branded pharmaceutical drugs. Generic versions of newly “off patented” products which are being developed and produced, include clavulanate, amoxicillin, omeprazole, ranitidine, loratadine, dexclorpheniramine, simvastatin and acyclovir.

In a DataMonitor report cited by the IMP3, with an annual anticipated growth rate of 7.5 per cent for the period 2005-2010, the global pharmaceutical market is projected to increase from USD534.8 billion in 2005 to USD762.2 billion by the end of 2010.

Patents of many drugs made by the US and European companies have either expired or will be expiring during the next few years. It is estimated that the patent expiry will involve about USD100 billion worth of branded drugs of major pharmaceutical companies. According to drug market research firm IMS Health, some USD16 billion worth of annual drug sales are expected to go off-patent in 2007 whereas in 2006, there was USD23 billion worth of patent expirations. Drugs with sales of USD160 billion are expected to come off patent by 2015, according to Datamonitor PLC (London, UK).

Joanna Chertkow, a pharmaceutical lead analyst at Datamonitor said, “It is expected that the raft of blockbuster patent expiries that will occur over the next ten years will lead to a rise in the volume of the generics market.”
This will create tremendous market opportunities for generics worldwide, which are expected to grow at an average annual rate of 10 per cent till 2011. For 2007, generics are expected to grow at the rate of 13 -14 per cent.

Moreover, there is also the relatively unexplored market for bio-generics which is estimated to grow at an annual average rate of 70 per cent during the period 2007-2011 and will generate a total revenue of more than USD16 billion by 2011.

For the IMP3 period, 2006-2020, investments in the pharmaceutical industry have been targeted at RM6.7 billion and exports are targeted to grow at an annual rate of 6.3 per cent to reach RM1.2 billion by 2020.

Indeed, our local generic drug manufacturers should seek to be globally competitive as in the theme in the IMP3 and fully exploit the opportunities available instead of lamenting on the negatives. The several strategic thrusts as set out in the IMP3 must necessarily be studied as to how to gain a greater share of the global pharmaceutical market, which, inter alia, include the encouraging of further efforts on R&D and commercialization, enhancing the development of expertise in drug research and the strengthening of the institutional support in the development and promotion of the industry.




jasoneight
Member
Posts: 3
IP Logged
Posted at 12:43:23 pm Apr 10, 2007
The article in the Sun mentioned that farmers in Malaysia will suffer if the MUFTA is signed but there are no details provided.

I remember some NGOs and other individual parties claimed in the press that our local farmers would be affected by the FTA, in that there will be an influx of rice from the US in the local market after the FTA and consequently affect local farmers.

But in fact, this is not the case.

In reality, rice production in Malaysia is not enough and we have to import 30 percent of our rice. This comes mainly from Vietnam which accounts for 420,000 tonnes or RM415 million worth of our rice import and from Thailand which accounts for some 300,00 tonnes of rice imports. This compares with only an import of 385 tonnes of rice from the US worth RM1.36 million.

If at all, then Malaysian rice is in fact competing with the rice from Vietnam and Thailand as the grade is the same, and not with that from the US, which is of a different grade and caters mainly to the Japanese and Koreans in the country.

Malaysian local white rice costs about RM2.20 per kilo while the rice from the US costs about RM10.25 per kilo. It is therefore clear that the rice from the US cannot compete with the local rice based on simple pricing and economics.


johnleemk
Infernally Rambling Thoughtless Mind
Head Administrator
Posts: 948
IP Logged
Posted at 1:23:48 pm Apr 10, 2007
Hm...nice research there, but your comments suspiciously resemble those of some government officials who have commented about the FTA, right down to the wording. :p
jasoneight
Member
Posts: 3
IP Logged
Posted at 1:34:34 pm Apr 11, 2007
The facts speak for themselves - plain and simple - not like those who mouth other sweeping, general and emotional statements.

These facts don't get reported in full often enough as they are not sensational and do not help sell papers.It is more dramatic to say that FTA destroy lives and take away our sovereignty.

Too often we forget how the Hong Kong economy was built.


Latest:
Change From Within? Not Likely
Popular:
An Exercise in Reciprocal Tolerance

Most Recently Read

  1. The Injustice of a Minimum Wage
  2. Fix Education for the Bumiputra
  3. Anwar and Altantuya, Twin Miscarriages of Justice
  4. Absence of Evidence is Not Evidence of Absence?
  5. Absolute vs Comparative Advantage
  6. Civil Law and Common Law
  7. Reform Malaysian Education at the Basic Levels
  8. Global Warming, True or False, Has No Bearing on the Environmental Question
  9. Economic Class and Education in Malaysia
  10. Ridiculosity in the Lina Joy Decision
Google
Latest active forum topics
Quoth the webserver...
Men who are unhappy, like men who sleep badly, are always proud of the fact.
— Bertrand Russell
Poll
Sorry, only registered users may vote. Please register or login.

There are currently no polls running.